PT1104294E - Composicoes e metodos de tratamento da proliferacao celular anormal - Google Patents
Composicoes e metodos de tratamento da proliferacao celular anormalInfo
- Publication number
- PT1104294E PT1104294E PT99933947T PT99933947T PT1104294E PT 1104294 E PT1104294 E PT 1104294E PT 99933947 T PT99933947 T PT 99933947T PT 99933947 T PT99933947 T PT 99933947T PT 1104294 E PT1104294 E PT 1104294E
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- compositions
- treatment
- vitamin
- cellular proliferation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
- A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/116,632 US20010002396A1 (en) | 1998-07-16 | 1998-07-16 | Compositions and methods of treating skin conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1104294E true PT1104294E (pt) | 2005-11-30 |
Family
ID=22368338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99933947T PT1104294E (pt) | 1998-07-16 | 1999-07-13 | Composicoes e metodos de tratamento da proliferacao celular anormal |
Country Status (12)
Country | Link |
---|---|
US (2) | US20010002396A1 (pt) |
EP (1) | EP1104294B8 (pt) |
JP (1) | JP2002527356A (pt) |
AT (1) | ATE305296T1 (pt) |
AU (1) | AU4988999A (pt) |
CA (1) | CA2337138A1 (pt) |
DE (1) | DE69927507T2 (pt) |
DK (1) | DK1104294T3 (pt) |
ES (1) | ES2249900T3 (pt) |
MX (1) | MXPA01000492A (pt) |
PT (1) | PT1104294E (pt) |
WO (1) | WO2000003700A1 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
AU762481C (en) * | 1998-03-27 | 2004-08-19 | Oregon Health Sciences University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
DE10010814A1 (de) * | 2000-03-08 | 2001-09-13 | Basf Ag | Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen |
IL153378A0 (en) * | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
US6566399B2 (en) * | 2000-08-03 | 2003-05-20 | Byung-Moo Min | Inhibitor of replicative senescence of human keratinocytes containing retinoic acid as active ingredients |
US20030191093A1 (en) * | 2001-12-03 | 2003-10-09 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
US7273607B2 (en) * | 2002-07-01 | 2007-09-25 | Karl G. Schakel, legal representative | Health enhancement method |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
ATE410184T1 (de) * | 2003-02-05 | 2008-10-15 | Galderma Res & Dev | Umkehremulsion mit mindestens einem gegenüber wasser empfindlichen wirkstoff und ihre anwendungen in kosmetik und dermatologie |
DK1603570T5 (da) * | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
US20060281813A1 (en) * | 2003-06-05 | 2006-12-14 | Charles Rubin | Methods of treating hyperproliferative cell disorders |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
FR2862540B1 (fr) * | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile |
US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
FR2871699A1 (fr) * | 2004-06-17 | 2005-12-23 | Galderma Sa | Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie |
US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
US20060177390A1 (en) * | 2005-02-08 | 2006-08-10 | Person John R | Skin cancer prevention method and product |
US20060073107A1 (en) * | 2004-10-04 | 2006-04-06 | Person John R | Use of vitamin D3 (cholecalciferol) in sunscreens |
US20100093674A1 (en) * | 2005-08-04 | 2010-04-15 | Person John R | Skin cancer prevention method and product |
US8034788B2 (en) * | 2005-05-10 | 2011-10-11 | Dermipsor Ltd. | Composition and methods for skin care |
US9173835B2 (en) | 2005-05-10 | 2015-11-03 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
WO2006133828A1 (en) * | 2005-06-17 | 2006-12-21 | Dsm Ip Assets B.V. | Novel use 25-hydroxycholecalciferol in combination with uv-b screening agents |
FR2894465B1 (fr) * | 2005-12-14 | 2010-09-10 | Fabre Pierre Dermo Cosmetique | Utilisation de composes polyinsatures en tant qu'agents blanchissants |
US20080275128A1 (en) * | 2007-04-27 | 2008-11-06 | Elliott C Lasser | Compositions and methods for the treatment of inflammatory conditions |
JP5978130B2 (ja) | 2009-08-14 | 2016-08-24 | バーグ エルエルシー | 脱毛症を治療するためのビタミンd3およびその類似体 |
US8747818B1 (en) * | 2011-02-07 | 2014-06-10 | Dennis Gross | Self-tanning compositions |
US11103520B2 (en) * | 2014-04-23 | 2021-08-31 | The Regents Of The University Of California | Analogs of N-acetlyglucosamine and uses thereof |
CA2950912A1 (en) * | 2014-06-04 | 2015-12-10 | Arbonne International, Llc | Clear compositions and methods for the delivery of active ingredients for skin care |
EP3939593A1 (en) * | 2014-09-10 | 2022-01-19 | Washington University | Compositions and methods for treatment of pre-cancerous skin lesions |
CA3092939A1 (en) * | 2018-03-07 | 2019-09-12 | Athenex HK Innovative Limited | Use of combination of kx01 and a vitamin d for treating hyperproliferative skin disorders |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514672A (en) | 1981-02-17 | 1996-05-07 | Bazzano; Gail S. | Use of retinoids and compositions containing same for hair growth |
WO1984002845A1 (en) * | 1983-01-21 | 1984-08-02 | Advanced Drug Tech | Vitamin-containing skin care ointment |
AU603340B2 (en) * | 1985-08-02 | 1990-11-15 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
JPS6360910A (ja) | 1986-09-01 | 1988-03-17 | Shiseido Co Ltd | 皮膚外用剤 |
US5763428A (en) * | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
GB9109733D0 (en) * | 1991-05-07 | 1991-06-26 | Unilever Plc | Cosmetic composition |
TW272187B (pt) | 1992-05-20 | 1996-03-11 | Hoffmann La Roche | |
US5547947A (en) * | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
FR2714595B1 (fr) | 1993-12-30 | 1996-02-02 | Oreal | Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement. |
DE69529043T2 (de) | 1994-09-30 | 2003-05-08 | L'oreal S.A., Paris | Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten |
US5786391A (en) | 1995-01-11 | 1998-07-28 | Cornell Research Foundation, Inc. | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position |
FR2738745B1 (fr) | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
-
1998
- 1998-07-16 US US09/116,632 patent/US20010002396A1/en not_active Abandoned
-
1999
- 1999-07-12 US US09/351,020 patent/US6242435B1/en not_active Expired - Fee Related
- 1999-07-13 EP EP99933947A patent/EP1104294B8/en not_active Expired - Lifetime
- 1999-07-13 WO PCT/US1999/015769 patent/WO2000003700A1/en active IP Right Grant
- 1999-07-13 AT AT99933947T patent/ATE305296T1/de not_active IP Right Cessation
- 1999-07-13 AU AU49889/99A patent/AU4988999A/en not_active Abandoned
- 1999-07-13 ES ES99933947T patent/ES2249900T3/es not_active Expired - Lifetime
- 1999-07-13 DK DK99933947T patent/DK1104294T3/da active
- 1999-07-13 DE DE69927507T patent/DE69927507T2/de not_active Expired - Fee Related
- 1999-07-13 PT PT99933947T patent/PT1104294E/pt unknown
- 1999-07-13 JP JP2000559835A patent/JP2002527356A/ja not_active Withdrawn
- 1999-07-13 MX MXPA01000492A patent/MXPA01000492A/es active IP Right Grant
- 1999-07-13 CA CA002337138A patent/CA2337138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA01000492A (es) | 2002-11-29 |
EP1104294A4 (en) | 2003-02-05 |
AU4988999A (en) | 2000-02-07 |
EP1104294B1 (en) | 2005-09-28 |
DE69927507D1 (de) | 2006-02-09 |
CA2337138A1 (en) | 2000-01-27 |
DK1104294T3 (da) | 2006-02-13 |
DE69927507T2 (de) | 2006-03-23 |
US20010002396A1 (en) | 2001-05-31 |
US6242435B1 (en) | 2001-06-05 |
ATE305296T1 (de) | 2005-10-15 |
EP1104294A1 (en) | 2001-06-06 |
EP1104294B8 (en) | 2005-11-23 |
JP2002527356A (ja) | 2002-08-27 |
WO2000003700A1 (en) | 2000-01-27 |
ES2249900T3 (es) | 2006-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1104294E (pt) | Composicoes e metodos de tratamento da proliferacao celular anormal | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
WO2003029418A3 (en) | Proliferation and differentiation of stem cells using extracellular matrix and other molecules | |
UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
BR9809279A (pt) | Procedimento para produção de uma fração de blocos g e/ou blocos m a partir de alginato | |
HK1071890A1 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
HK1091400A1 (en) | Pharmaceutical compositions and methods for accelerating wound healing | |
EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
AU5624699A (en) | Use of 5ht-6 antagonists | |
BR9811099A (pt) | Inibidores de urocinase | |
YU7797A (sh) | Kombinovana terapija za osteoporozu | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
WO1998058911A3 (en) | Prostaglandin agonists | |
SE9602818D0 (sv) | Colored composition | |
NO963462L (no) | Paramunitetinducer basert på kombinasjoner av poxvirus komponenter, fremgangsmåte for fremstilling derav og anvendelse som medikament | |
HUP9802303A2 (hu) | Kalcitriolszármazékok és gyógyászati alkalmazásuk | |
AU8647101A (en) | Compounds having activity as inhibitors of cytochrome p450rai | |
PL336640A1 (en) | Substituted 3,3-diamino-2- propenonitriles, their production and application | |
BR0315247A (pt) | Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit | |
BG105264A (en) | New use of taxoid derivatives | |
PL331241A1 (en) | Colour composition including an agent containing pyrogallol units, iron (ii) salt and organic acid | |
DE69613395D1 (de) | Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel | |
MX9704948A (es) | Retinoides triciclicos, metodos para su produccion y uso. | |
AU3862997A (en) | Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof |